Welcome to our dedicated page for Rein Therapeutics SEC filings (Ticker: RNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rein Therapeutics, Inc. (RNTX) SEC filings page brings together the company’s official U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and registration statements that describe its clinical programs, financing arrangements, and regulatory milestones. These documents provide primary-source detail on how the clinical-stage biopharmaceutical company is advancing therapies for idiopathic pulmonary fibrosis (IPF) and other orphan pulmonary and fibrosis indications.
Among the most relevant filings for RNTX are multiple Form 8-K reports. These include descriptions of the Phase 2 RENEW trial of LTI-03 in IPF, FDA communications regarding a clinical hold and its subsequent resolution, and regulatory authorizations from European agencies for trial sites in the United Kingdom, Germany, and Poland. Other 8-Ks outline the structure and terms of a Pre-Paid Advance Agreement and a Standby Equity Purchase Agreement with an affiliate of Yorkville Advisors, as well as later disclosure that Rein elected to terminate these agreements after taking specified advances and without incurring penalties.
Investors can also review the company’s S-1 registration statement, which summarizes Rein’s business overview, risk factors, and details of the Yorkville standby equity facility, including the number of shares registered for potential resale. Together, these filings explain how Rein describes its lead candidate LTI-03, its second candidate LTI-01 for loculated pleural effusions, and the associated orphan drug and Fast Track designations.
On Stock Titan, AI-powered tools can help interpret lengthy RNTX filings by highlighting key sections on clinical trial design, regulatory status, and financing terms. Users can quickly locate information on material agreements, capital structure changes, and important clinical or regulatory events disclosed in Rein Therapeutics’ SEC documents.
Rein Therapeutics, Inc. (RNTX) furnished an investor presentation highlighting its lead product candidate LTI-03, an inhaled caveolin-1 scaffolding domain peptide in development for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases. The company describes LTI-03 as a first-in-class, excipient-free dry powder therapy designed to restore caveolin-1 signaling, support alveolar epithelial cell survival, and attenuate multiple profibrotic pathways.
The presentation reports that a Phase 1b trial in IPF patients tested 5 mg and 10 mg once-daily inhaled LTI-03 over 14 days in 24 participants, met its safety and tolerability objectives with no treatment-related serious adverse events, and showed exploratory biomarker changes, including a 4.6% reduction in plasma surfactant protein D at the 10 mg dose over two weeks. Preclinical and ex vivo models demonstrate broad antifibrotic and regenerative activity in lung and other organs, and a Phase 2 RENEW trial (NCT06968845) is now enrolling. Rein also notes forward-looking risks, including the possibility that existing cash may not fund operations into the first quarter of 2028.
Rein Therapeutics, Inc. (RNTX) reported receiving a Nasdaq delisting notice on August 21, 2026, because its common stock’s closing bid price was below $1.00 per share for the prior 30 consecutive trading days, violating Nasdaq Listing Rule 5550(a)(1).
Under Nasdaq Rule 5810(c)(3)(A), Rein Therapeutics has 180 days, until February 17, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If it does not regain compliance, it may seek an additional extension period if it meets other Nasdaq Capital Market initial listing standards, but there is no assurance that extra time will be granted. Failure to regain compliance would lead Nasdaq to begin suspension and delisting procedures for the company’s common stock.
ADAR1 Capital Management, LLC and its manager, Daniel Schneeberger, report beneficial ownership in Rein Therapeutics, Inc. They report 4,500,000 shares of common stock, representing 5.3% of the company’s common stock outstanding.
The shares are held by private investment funds managed by ADAR1 Capital Management and may be deemed to be indirectly beneficially owned by both ADAR1 Capital Management and Mr. Schneeberger. The percentage is based on 85,767,032 shares of common stock outstanding as of June 30, 2026.
Lynwood Capital Management Inc., Ben Shapiro and Lynwood Opportunities Master Fund reported beneficial ownership of 4,280,500 shares of Rein Therapeutics, Inc. common stock, representing 5.0% of the class. The shares are directly held by the Fund, with the Investment Manager and Mr. Shapiro deemed beneficial owners through control of the Fund.
The ownership percentages are based on 85,539,032 shares of common stock outstanding as of May 21, 2026. Each reporting person has sole voting and dispositive power over the 4,280,500 shares and disclaims beneficial ownership of any other shares.
Rein Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on fibrotic diseases and reported results for the three and six months ended June 30, 2026. The company’s lead candidate LTI-03 for idiopathic pulmonary fibrosis is in the Phase 2 RENEW trial, a multi-center randomized, double-blind, placebo-controlled study targeting about 120 patients, with interim data anticipated in the fourth quarter of 2026. Development of LTI-01 remains paused indefinitely to prioritize LTI-03.
The company generated no revenue and recorded a net loss of $6.4 million for the quarter and $12.2 million for the first half of 2026, similar to 2025. Operating expenses for the first half were $11.3 million, primarily research and development. As of June 30, 2026, cash, cash equivalents and investments totaled $43.6 million, and total assets were $66.0 million.
In May 2026, Rein completed an underwritten common stock offering of 57.5 million shares at $1.00 per share, raising gross proceeds of $57.5 million and net proceeds of approximately $53.1 million. Management states that available cash, cash equivalents and investments are expected to fund planned operations, including completion of the Phase 2 RENEW trial, into the first quarter of 2028. The company has an accumulated deficit of $413.5 million and continues to expect operating losses for the foreseeable future.
Rein Therapeutics, Inc. has a significant shareholder, Laurence W. Lytton, reporting updated ownership of its common stock. Lytton beneficially owns 4,238,628 shares of common stock, representing 4.9% of the class, based on 85,539,032 shares outstanding as of May 13, 2026. He reports sole voting power and sole dispositive power over all 4,238,628 shares, with no shared voting or dispositive power. This amendment reflects that his holdings are now reported as ownership of 5 percent or less of the outstanding common stock.
Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on July 20, 2026. Stockholders elected Class III directors Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D., with about 25.4 million votes for and 13.2 million votes withheld for each, plus 25,098,629 broker non-votes.
Stockholders approved an amendment to the restated certificate of incorporation to increase authorized common stock from 100 million shares to 200 million shares, with 61,004,221 votes for, 2,394,208 against, and 305,605 abstentions. They also ratified CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the compensation of named executive officers.
Rein Therapeutics, Inc. is the subject of an Amendment No. 3 to a Schedule 13G filed by a group of Voss-managed investment entities and Travis W. Cocke reporting their beneficial ownership of the company’s common stock.
Voss Value Master Fund beneficially owned 1,000,000 shares (about 1.2% of the class) and Voss Value-Oriented Special Situations Fund owned 500,000 shares (about 0.6%). Through their roles as general partner and investment manager, Voss Advisors GP, LLC and Voss Capital, L.P. may be deemed to beneficially own these shares plus 4,156,957 shares held in Voss Managed Accounts, for aggregate beneficial ownership of 5,656,957 shares, or approximately 6.6% of Rein Therapeutics’ outstanding common stock. Travis W. Cocke, as managing member of Voss Capital and Voss GP, may likewise be deemed to beneficially own 5,656,957 shares, or about 6.6%. Percentages are based on 85,539,032 shares outstanding as of May 13, 2026.
Rein Therapeutics is asking stockholders to vote at its virtual 2026 annual meeting on July 20, 2026. Holders of 85,539,032 shares of common stock outstanding as of May 21, 2026 may participate and vote online.
Key items include electing two Class III directors to terms ending in 2029, approving an amendment to double authorized common shares from 100 million to 200 million, ratifying CBIZ CPAs P.C. as auditor for 2026, and an advisory vote on named executive officer compensation. The proxy also outlines the company’s classified board, committee structure, insider trading, anti-hedging and clawback policies, and details executive pay, including a $575,000 base salary and $287,500 bonus for the CEO in 2025.